Point72 Asset Management’s Edwards Lifesciences EW Stock Holding History

Point72 Asset Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-21,300	Closed	-$1.82M	–	3990
2025 Q4	$1.82M	Buy	21,300 +17,400	+446%	+$1.43M	﹤0.01%	2530
2025 Q3	$303K	Buy	3,900 +3,100	+388%	+$242K	﹤0.01%	2065
2025 Q2	$62.6K	Buy	+800	New	+$59.7K	﹤0.01%	2092
2024 Q2	–	Sell	-5,600	Closed	-$535K	–	2019
2024 Q1	$535K	Hold	5,600	–	–	﹤0.01%	1630
2023 Q4	$427K	Hold	5,600	–	–	﹤0.01%	1626
2023 Q3	$388K	Buy	+5,600	New	+$450K	﹤0.01%	1588

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Point72 Asset Management's EW Position: Q1 2026 in Review

Point72 Asset Management increased its Edwards Lifesciences (EW) stake by 311% in Q1 2026, buying an estimated $114M and bringing the position to 1,826,537 shares worth $146M. The position accounts for 0.19% of the portfolio, ranked #101.

Point72 Asset Management first reported a position in EW in Q3 2014 and has held it in 34 quarters since. The position peaked at $284M in Q1 2024. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

Point72 Asset Management held 1,826,537 shares of Edwards Lifesciences worth $146M as of Q1 2026.
Point72 Asset Management bought 1,382,170 Edwards Lifesciences shares in Q1 2026, an estimated $114M.
Edwards Lifesciences made up 0.19% of Point72 Asset Management's portfolio in Q1 2026, its #101 holding.
Point72 Asset Management first reported a position in Edwards Lifesciences in Q3 2014 and has held it in 34 quarters since.
Point72 Asset Management's Edwards Lifesciences position peaked at $284M in Q1 2024.
1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.